Critical Comparison: Nano-X Imaging (NASDAQ:NNOX) vs. AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ:ANGO) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares AngioDynamics and Nano-X Imaging’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-10.12%	-4.49%	-2.96%
Nano-X Imaging	-926.05%	-116.93%	-100.67%

Risk and Volatility

AngioDynamics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Nano-X Imaging has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Insider and Institutional Ownership

89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are held by institutional investors. 6.0% of AngioDynamics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares AngioDynamics and Nano-X Imaging”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$320.17 million	1.59	-$36.74 million	($0.78)	-15.47
Nano-X Imaging	$13.02 million	2.26	-$75.02 million	($2.14)	-0.17

AngioDynamics has higher revenue and earnings than Nano-X Imaging. AngioDynamics is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for AngioDynamics and Nano-X Imaging, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	1	1	2	1	2.60
Nano-X Imaging	1	2	2	1	2.50

AngioDynamics presently has a consensus target price of $19.00, suggesting a potential upside of 57.42%. Nano-X Imaging has a consensus target price of $4.33, suggesting a potential upside of 1,060.82%. Given Nano-X Imaging’s higher probable upside, analysts plainly believe Nano-X Imaging is more favorable than AngioDynamics.

Summary

AngioDynamics beats Nano-X Imaging on 9 of the 13 factors compared between the two stocks.

About AngioDynamics

AngioDynamics, Inc. develops, manufactures and markets medical devices used in minimally invasive procedures. Its products are designed for clinicians in areas including vascular access, peripheral vascular disease and oncology. The company’s offerings include vascular access devices such as ports and catheters, as well as technologies used in vascular intervention and cancer treatment. These include the Auryon atherectomy system, which is used to treat certain peripheral arterial conditions, and the NanoKnife System, which uses irreversible electroporation in tumor ablation procedures.

About Nano-X Imaging

Nano-X Imaging Ltd. is an Israel-based medical technology company focused on expanding access to diagnostic imaging. The company develops digital X-ray systems and related technologies designed to provide medical imaging in locations that may have limited access to conventional radiology equipment. Its primary product is the Nanox.ARC, a digital tomosynthesis system intended to generate two- and three-dimensional medical images using a proprietary cold-cathode X-ray source. Nano-X also offers the Nanox.CLOUD platform, which is designed to connect imaging devices with radiologists and other healthcare professionals for image interpretation, workflow management, and related services.